This study looks at the long-term safety of nivolumab and other cancer treatments for patients who have previously participated in trials. The goal is to understand how well these treatments work over time for different types of cancer. Researchers want to ensure that patients continue to receive effective care and support.
The trial ID is NCT03899155. This is a Phase 2 study, which means researchers are investigating how well the treatments work and how safe they are. The study is regulated by the FDA and aims to include around 1,500 participants.
Who can join
Adults aged 18 and older can join this study. It is open to both men and women. Participants must have previously been in a study involving nivolumab and meet specific health criteria. The study team will confirm who is eligible to take part.
Condition
Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will receive one of several treatment options. These include different doses of nivolumab alone or in combination with other medications like ipilimumab or relatlimab. Everyone will not receive the same treatment, as participants will be grouped based on what is best for them.
Where
This trial is enrolling at 59 locations. Recruiting sites are listed first.
Dana_Farber Cancer Institute (DFCI)
Boston, Massachusetts
Recruiting
Lancaster General Health
Lancaster, Pennsylvania
Recruiting
NYU Langone Hematology Oncology Associates-Mineola
Mineola, New York
Recruiting
Oncology Hematology Care
Cincinnati, Ohio
Recruiting
Roswell Park Cancer Institute
Buffalo, New York
Recruiting
Tennesse Oncology
Nashville, Tennessee
Recruiting
The Ohio University
Columbus, Ohio
Recruiting
University of Louisville-James Graham Brown Cancer Center
Louisville, Kentucky
Recruiting
Study contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com